• SPX
  • $5,928.76
  • 0.2 %
  • $11.65
  • DJI
  • $43,763.58
  • 0.82 %
  • $355.10
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,151.19
  • 0.82 %
  • $66.12
  • IXIC
  • $18,884.71
  • -0.43 %
  • -$81.43
App Store Download on the App Store Google Play GET IT ON Google Play

Get The App

App Store Download on the App Store Google Play GET IT ON Google Play
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price, News & Analysis

Currency in USD Disclaimer

$322.38

$5.29

(1.66%)

Day's range
$315.15
Day's range
$323.99
50-day range
$200.63
Day's range
$368.29
  • Country: US
  • ISIN: US5588681057
52 wk range
$168.25
Day's range
$368.29


We are preparing, please wait

1 Hour 1 Day 1 Week 1 Year Advanced Chart
Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.25
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (MDGL)
  • Company Madrigal Pharmaceuticals, Inc.
  • Price $322.38
  • Changes Percentage (1.66%)
  • Change $5.29
  • Day Low $315.15
  • Day High $323.99
  • Year High $368.29

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $355.50
  • High Stock Price Target $410.00
  • Low Stock Price Target $111.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$23.15
  • Trailing P/E Ratio -10.55
  • Forward P/E Ratio -10.55
  • P/E Growth -10.55
  • Net Income $-373,630,000

Income Statement

Quarterly

Annual

Latest News of MDGL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

View ALL
Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Madrigal Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of MDGL in the last quarter?

    In the last quarter Madrigal Pharmaceuticals, Inc. earnings were on Thursday, October, 31st. The Madrigal Pharmaceuticals, Inc. maker reported -$4.92 EPS for the quarter, beating analysts' consensus estimates of -$6.94 by $2.02.

  • What is the Madrigal Pharmaceuticals, Inc. stock price today?

    Today's price of Madrigal Pharmaceuticals, Inc. is $322.38 — it has increased by +1.66% in the past 24 hours. Watch Madrigal Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Madrigal Pharmaceuticals, Inc. release reports?

    Yes, you can track Madrigal Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Madrigal Pharmaceuticals, Inc. stock forecast?

    Watch the Madrigal Pharmaceuticals, Inc. chart and read a more detailed Madrigal Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Madrigal Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Madrigal Pharmaceuticals, Inc. stock ticker.

  • How to buy Madrigal Pharmaceuticals, Inc. stocks?

    Like other stocks, MDGL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Madrigal Pharmaceuticals, Inc.'s EBITDA?

    Madrigal Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Madrigal Pharmaceuticals, Inc.’s financial statements.

  • What is the Madrigal Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Madrigal Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Madrigal Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Madrigal Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Madrigal Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Madrigal Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Madrigal Pharmaceuticals, Inc. for its last quarter?

    Madrigal Pharmaceuticals, Inc. published it's last quarterly revenues at $62.18 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

or
download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Sign Up With Email Address
or
google app download Continue with Google ios app download Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.